Cephalosporins are potent SARS-CoV-2 main protease inhibitors

The SARS-CoV-2 main protease (M^pro) plays a pivotal role in viral replication and is a validated therapeutic target. Previous work has revealed that derivatives of clinically used penicillin Antibiotics can inhibit M^proin vitro through non-covalent binding at the active site or formation of stable acyl-enzyme complexes via reaction of the nucleophilic Cys145 with the penicillin β-lactam ring. Here we demonstrate that cephalosporin derivatives are substantially more potent inhibitors of isolated M^pro than the reported penicillin derivatives. Structure-activity relationship and computational studies reveal the importance of appropriate cephalosporin C3 substitution in modulating inhibition potency and mechanism, with both covalent reaction with Cys145 and non-covalent active site binding being observed. Cephalosporin derivatives also show potential for inhibiting SARS-CoV-2 replication in infected cells. The combined results imply that the cephalosporin scaffold may be of use for development of Antiviral drugs targeting the SARS-CoV-2 proteases and, by implication, Other nucleophilic cysteine proteases. They further highlight the potential of bicyclic β-lactams for therapeutic applications beyond their established use as Antibiotics inhibiting Bacterial nucleophilic serine transpeptidases.

COVID-19; Cephalosporin antibiotics; Covalently reacting inhibitors; M(pro); Nucleophilic cysteine inhibition; Protease inhibitors; SARS-CoV-2 main protease; β-Lactam.